See more : Triad Guaranty Inc. (TGIC) Income Statement Analysis – Financial Results
Complete financial analysis of Standard BioTools Inc. (LAB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Standard BioTools Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- KONNDOR INDUSTRIES LIMITED (KONNDOR.BO) Income Statement Analysis – Financial Results
- Niche-Tech Group Limited (8490.HK) Income Statement Analysis – Financial Results
- Metal Sky Star Acquisition Corporation (MSSA) Income Statement Analysis – Financial Results
- GoPro, Inc. (5G5.DE) Income Statement Analysis – Financial Results
- Hyosung Advanced Materials Corporation (298050.KS) Income Statement Analysis – Financial Results
Standard BioTools Inc. (LAB)
About Standard BioTools Inc.
Standard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, Advanta Dx SARS-CoV-2 RT-PCR assays, Advanta Dx COVID-19 EASE assays, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 systems; preparatory analytical instruments, which include C1 IFCs; and software solutions. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. Standard BioTools Inc. has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2001 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 106.34M | 97.95M | 130.58M | 138.14M | 117.24M | 112.96M | 101.94M | 104.45M | 114.71M | 116.46M | 71.18M | 52.33M | 42.87M | 33.56M | 25.41M | 15.35M | 7.28M | 6.40M | 130.58M |
| Cost of Revenue | 55.89M | 60.90M | 61.21M | 54.82M | 52.96M | 51.32M | 49.96M | 46.01M | 46.63M | 42.85M | 20.08M | 15.33M | 13.19M | 11.58M | 11.49M | 8.36M | 3.51M | 2.77M | 53.32M |
| Gross Profit | 50.45M | 37.05M | 69.37M | 83.33M | 64.28M | 61.65M | 51.98M | 58.44M | 68.08M | 73.61M | 51.10M | 37.01M | 29.67M | 21.98M | 13.93M | 6.98M | 3.76M | 3.63M | 77.27M |
| Gross Profit Ratio | 47.44% | 37.83% | 53.13% | 60.32% | 54.83% | 54.57% | 50.99% | 55.95% | 59.35% | 63.21% | 71.79% | 70.72% | 69.23% | 65.49% | 54.80% | 45.50% | 51.70% | 56.66% | 59.17% |
| Research & Development | 25.95M | 38.50M | 37.94M | 36.46M | 31.64M | 30.03M | 30.83M | 38.42M | 39.26M | 43.42M | 19.73M | 16.60M | 13.94M | 13.01M | 12.32M | 14.02M | 14.39M | 15.59M | 37.94M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 87.54M | 114.76M | 98.89M | 97.90M | 84.48M | 79.78M | 79.52M | 93.21M | 82.96M | 71.32M | 48.06M | 38.48M | 31.30M | 23.55M | 19.65M | 22.51M | 12.90M | 9.70M | 98.89M |
| Other Expenses | 0.00 | -12.31M | 7.63M | 507.00K | 1.43M | 637.00K | 385.00K | -1.17M | -1.16M | -857.00K | 502.00K | -189.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.89M |
| Operating Expenses | 113.49M | 153.26M | 136.83M | 134.36M | 116.12M | 109.81M | 110.34M | 131.63M | 122.22M | 114.75M | 67.79M | 55.08M | 45.24M | 36.55M | 31.96M | 36.53M | 27.29M | 25.29M | 144.73M |
| Cost & Expenses | 169.38M | 214.15M | 198.04M | 189.18M | 169.08M | 161.13M | 160.30M | 177.64M | 168.85M | 157.60M | 87.87M | 70.41M | 58.43M | 48.13M | 43.45M | 44.89M | 30.80M | 28.06M | 198.04M |
| Interest Income | 0.00 | 4.33M | 291.00K | 307.00K | 1.33M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.00K | 37.00K | 766.00K | 1.14M | 565.00K | 0.00 |
| Interest Expense | 4.57M | 4.33M | 3.82M | 3.57M | 4.28M | 13.89M | 5.82M | 5.82M | 5.81M | 5.34M | 14.00K | 628.00K | 3.10M | 2.16M | 2.88M | 2.03M | 2.79M | 2.26M | -3.82M |
| Depreciation & Amortization | 15.18M | 15.03M | 16.07M | 17.94M | 15.81M | 16.50M | 18.30M | 17.94M | 16.12M | 4.06M | 2.55M | 1.48M | 1.06M | 1.50M | 1.94M | 1.97M | 2.14M | 1.46M | 0.00 |
| EBITDA | -54.46M | -173.57M | -43.77M | -34.61M | -46.62M | -31.03M | -39.68M | -56.42M | -32.87M | -38.50M | -13.82M | -16.78M | -18.14M | -13.52M | -14.67M | -26.12M | -20.91M | -19.83M | -67.46M |
| EBITDA Ratio | -51.21% | -115.87% | -33.89% | -25.05% | -29.51% | -27.40% | -38.62% | -54.02% | -34.16% | -32.58% | -19.15% | -32.06% | -33.84% | -38.92% | -63.20% | -174.69% | -278.32% | -306.96% | -51.66% |
| Operating Income | -76.60M | -116.21M | -67.46M | -51.04M | -51.84M | -48.16M | -58.36M | -73.19M | -50.16M | -51.84M | -17.95M | -18.07M | -18.57M | -14.57M | -18.04M | -29.54M | -23.53M | -21.66M | -67.46M |
| Operating Income Ratio | -72.03% | -118.64% | -51.66% | -36.94% | -44.22% | -42.64% | -57.25% | -70.07% | -43.72% | -44.51% | -25.22% | -34.53% | -43.31% | -43.42% | -70.98% | -192.50% | -323.38% | -338.59% | -51.66% |
| Total Other Income/Expenses | 2.40M | -76.72M | 3.80M | -3.07M | -14.87M | -13.26M | -5.44M | -6.99M | -4.64M | -5.87M | 2.26M | -817.00K | -3.74M | -2.25M | -1.14M | -103.00K | -1.82M | -1.89M | 3.80M |
| Income Before Tax | -74.20M | -192.93M | -63.66M | -54.10M | -66.71M | -61.42M | -63.80M | -80.18M | -54.79M | -57.71M | -15.69M | -18.89M | -22.30M | -16.82M | -19.18M | -29.65M | -25.35M | -23.55M | -63.66M |
| Income Before Tax Ratio | -69.78% | -196.97% | -48.75% | -39.16% | -56.89% | -54.37% | -62.59% | -76.76% | -47.76% | -49.55% | -22.03% | -36.09% | -52.03% | -50.12% | -75.47% | -193.17% | -348.40% | -368.13% | -48.75% |
| Income Tax Expense | 452.00K | -2.83M | -4.42M | -1.08M | -1.92M | -2.41M | -3.26M | -4.19M | -1.48M | -4.88M | 137.00K | 136.00K | 166.00K | 83.00K | -50.00K | -147.00K | 105.00K | 194.00K | -4.42M |
| Net Income | -74.66M | -190.10M | -59.24M | -53.02M | -64.79M | -59.01M | -60.54M | -75.99M | -53.32M | -52.83M | -15.82M | -19.02M | -22.47M | -16.90M | -19.13M | -29.50M | -25.45M | -23.55M | -59.24M |
| Net Income Ratio | -70.21% | -194.08% | -45.36% | -38.38% | -55.26% | -52.24% | -59.38% | -72.75% | -46.48% | -45.36% | -22.23% | -36.35% | -52.42% | -50.36% | -75.27% | -192.21% | -349.84% | -368.13% | -45.36% |
| EPS | -0.94 | -2.43 | -0.78 | -0.74 | -0.97 | -1.49 | -1.84 | -2.62 | -1.86 | -1.90 | -0.62 | -0.86 | -1.26 | -0.89 | -11.02 | -17.85 | -13.47 | -12.46 | 0.00 |
| EPS Diluted | -0.94 | -2.43 | -0.78 | -0.74 | -0.97 | -1.49 | -1.84 | -2.62 | -1.86 | -1.90 | -0.62 | -0.86 | -1.26 | -0.89 | -11.02 | -17.85 | -13.47 | -12.46 | 0.00 |
| Weighted Avg Shares Out | 79.16M | 78.31M | 75.79M | 72.04M | 66.78M | 39.65M | 32.98M | 29.01M | 28.71M | 27.77M | 25.48M | 22.14M | 17.85M | 18.98M | 1.74M | 1.65M | 1.89M | 1.89M | 0.00 |
| Weighted Avg Shares Out (Dil) | 79.16M | 78.31M | 75.79M | 72.04M | 66.78M | 39.65M | 32.98M | 29.01M | 28.71M | 27.77M | 25.48M | 22.14M | 17.85M | 18.98M | 1.74M | 1.65M | 1.89M | 1.89M | 0.00 |
STANDARD BIOTOOLS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Standard BioTools Inc. - LAB
Standard BioTools and SomaLogic Announce Date for Special Meetings of Stockholders to Vote on Proposed Merger
Standard BioTools Inc. (LAB) Q3 2023 Earnings Call Transcript
Standard BioTools Reports Third Quarter and Year-to-Date 2023 Financial Results
Standard BioTools to Present at the Jefferies London Healthcare Conference
Standard BioTools Announces Conference Call and Webcast of Third Quarter 2023 Financial Results on November 7, 2023
Best Penny Stocks This Week? 3 To Watch During Earnings Season
STANDARD BIOTOOLS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Standard BioTools Inc. - LAB
LAB INVESTOR ALERT: Julie & Holleman LLP Announces Investigation of Proposed Merger Between Standard BioTools and SomaLogic
LAB Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Standard BioTools Inc. Is Fair to Shareholders
Source: https://incomestatements.info
Category: Stock Reports